haemophilia

Pfizer moves haemophilia gene therapy into phase 3

https://pharmaphorum.com/r-d/pfizer-haemophilia-b-gene-therapy/

Europe: thumbs up for Roche’s Hemlibra, Chiesi rare disease drug, bad news for Santhera

https://pharmaphorum.com/news/roches-haemophilia-drug-poised-hit-eu-market/

After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bn

https://pharmaphorum.com/news/losing-two-big-deals-sanofi-buys-bioverativ-11-6bn/

‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine

https://pharmaphorum.com/news/cure-hemophilia-within-reach-biomarin-spark-gene-therapies-shine/

Spark and Pfizer’s gene therapy wows in haemophilia B

https://pharmaphorum.com/news/spark-pfizers-gene-therapy-wows-haemophilia-b/

Roche double trial success could expand use of two new drugs

https://pharmaphorum.com/news/roche-double-trial-success-expand-use-two-new-drugs/

FDA approves Roche potential haemophilia blockbuster

https://pharmaphorum.com/news/fda-approves-roche-potential-haemophilia-blockbuster/

A gamechanger in haemophilia? SOBI unruffled by Roche’s impending therapy

https://pharmaphorum.com/news/gamechanger-haemophilia-sobi-unruffled-roches-impending-therapy/

Breakthrough status for BioMarin ratchets up haemophilia A competition

https://pharmaphorum.com/news/breakthrough-status-biomarin-ratchets-haemophilia-competition/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search